"Vedolizumab has clinical promise as a potential treatment option for
people with moderate to severely active Crohn's and UC," said Paul
Rutgeerts M.D., Ph.D., of the Catholic University of Leuven in Belgium."While
there is no known cure, there is a need for new CD and UC treatment
options, in an effort to provide patients with additional choices for
managing their disease, reducing symptoms and achieving remission," he
added.
Source: Sandborn W, Feagan B, Rutgeerts P, et al. Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 2013;369;8:711-721.
#DemocracygoOut!
Clinical data of 814 patients with Crohn's disease: 41.8% can heal with Vedolziumab after 52 weeks.But 4 people didn't survive Vedolziumab!
— Censored31 (@Censored31) August 24, 2013
Klinische gegevens van 814 patiënten met de ziekte van Crohn: 41,8% kan genezen met Vedolziumab na 52 weken. 4 overleefden Vedolziumab niet!
— Censored31 (@Censored31) August 24, 2013
Source: Sandborn W, Feagan B, Rutgeerts P, et al. Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 2013;369;8:711-721.
#DemocracygoOut!
